Home » Stocks » ADXS

Advaxis, Inc. (ADXS)

Stock Price: $0.285 USD -0.003 (-0.90%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.288 +0.003 (0.91%) Nov 27, 4:58 PM

Stock Price Chart

Key Info

Market Cap 18.89M
Revenue (ttm) 254,000
Net Income (ttm) -30.20M
Shares Out 66.23M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $0.285
Previous Close $0.288
Change ($) -0.003
Change (%) -0.90%
Day's Open 0.300
Day's Range 0.272 - 0.308
Day's Volume 8,573,851
52-Week Range 0.264 - 1.480

More Stats

Market Cap 18.89M
Enterprise Value 1.28M
Earnings Date (est) Dec 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 66.23M
Float 61.55M
EPS (basic) -0.49
EPS (diluted) -0.56
FCF / Share -0.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.51M
Short Ratio 0.50
Short % of Float 2.45%
Beta 3.49
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 74.39
PB Ratio 0.81
Revenue 254,000
Operating Income -30.34M
Net Income -30.20M
Free Cash Flow -27.75M
Net Cash 17.62M
Net Cash / Share 0.27
Gross Margin 8,222.05%
Operating Margin -11,942.91%
Profit Margin -11,888.60%
FCF Margin -10,923.62%
ROA -36.43%
ROE -74.81%
ROIC -243.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.00*
Low
5.00
Current: $0.285
High
5.00
Target: 5.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue20.886.0612.033.99-1.00---0.51
Revenue Growth244.45%-49.61%201.16%-------
Gross Profit20.886.0612.033.99-1.00---0.51
Operating Income-17.97-70.38-98.45-76.49-48.70-19.54-14.69-12.33-13.02-7.93
Net Income-16.61-66.52-93.44-73.56-47.03-16.53-19.99-12.07-8.12-10.81
Shares Outstanding15.213.432.702.361.871.140.330.170.120.08
Earnings Per Share-1.09-19.36-34.65-31.20-25.20-14.55-61.50-74.85-75.00-131.24
Operating Cash Flow-36.13-62.13-76.84-9.14-24.16-16.08-8.71-4.57-8.94-6.42
Capital Expenditures0.03-1.43-3.45-3.22-0.97-0.02-0.02-0.09--0.01
Free Cash Flow-36.10-63.55-80.29-12.37-25.14-16.11-8.74-4.66-8.94-6.44
Cash & Equivalents32.3645.1270.8915211217.6120.550.001.100.11
Total Debt----0.030.060.232.826.071.44
Net Cash / Debt32.3645.1270.8915211217.5420.33-2.82-4.97-1.33
Assets45.2662.2793.6416912023.3823.593.825.362.88
Liabilities5.7338.2239.3849.744.012.755.589.7817.9217.68
Book Value39.5324.0554.2611911620.6318.00-5.96-12.57-14.80
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Advaxis, Inc.
Country United States
Employees 35
CEO Kenneth A. Berlin

Stock Information

Ticker Symbol ADXS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADXS

Description

Advaxis, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.